A5013410369- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Nail Diseases and Treatments
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Autoimmune Bullous Skin Diseases
- T-cell and Retrovirus Studies
- Cancer and Skin Lesions
- Fungal Infections and Studies
- Mast cells and histamine
- Vascular Tumors and Angiosarcomas
- Dermatology and Skin Diseases
- Autoimmune and Inflammatory Disorders
- Ocular Oncology and Treatments
- Sarcoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Eosinophilic Disorders and Syndromes
- melanin and skin pigmentation
- Receptor Mechanisms and Signaling
Klinikum Ludwigshafen
2016-2025
Ludwigshafen University of Business and Society
2017-2022
Ludwig-Maximilians-Universität München
2005-2020
Eastern Cooperative Oncology Group
2020
LMU Klinikum
2020
Princess Margaret Cancer Centre
2019
Johannes Gutenberg University Mainz
2010-2014
Advanced Dermatology
2013
Arbeitsgemeinschaft Dermatologische Onkologie
2012
University Medical Centre Mannheim
2001-2007
This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of Dermatological Society (DDG) and Dermatologic Cooperative Oncology Group (DeCOG) funded by Guideline Program in Oncology.The recommendations are based on a systematic literature search, consensus 32 medical societies, working groups patient representatives.This contains concerning diagnosis, therapy follow-up melanoma.The diagnosis primary clinical features dermoscopic criteria.It is...
Cutaneous lymphomas (CL) are categorized as extranodal non-Hodgkin lymphomas, constituting the second most common form in this group (MALT of stomach form). Their incidence is estimated at one new diagnosis per 100,000 inhabitants year Germany [1-3]. Primary CL, by definition, present skin first, and time after staging completed do not show any involvement other organs. Secondary on hand, cutaneous manifestations disseminated [4], primarily nodal or leukemias. CL comprise a large, clinically...
PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one few biomarkers predicting ICI therapy outcome. The objective present study was to systematically investigate whether type tumor tissue examined for has an impact on correlation with outcome.Pre-treatment collected within prospective DeCOG cohort ADOREG/TRIM (CA209-578; NCT05750511) between February 2014 and May 2020 from 448 consecutive patients who received...
Abstract Sentinel lymph node biopsy for several cancers has shown that metastatic tumour cells are preferentially arrested in the sinuses. To study molecular components of this sinusoidal trap, gene profiling (sinuses) versus tonsil (no sinuses) was performed. Among other groups molecules, an intriguing signature scavenger and lectin‐like receptors identified. Nine 13 genes were expressed by immunohistochemistry. Using stabilin‐2 monoclonal antibody 3A5 as exclusive endothelial cell (EC)...
Summary Background : Primary cutaneous lymphomas form a heterogenous group of lymphatic neoplasias.They manifest themselves on the skin and are second most frequent non‐Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.The number epidemiologic studies is small due to limited availability comparability population‐based data. Patients methods In present study first evaluation German Central Registry for Cutaneous Lymphomas (ZRKL) Society Dermatology (DDG) undertaken basis 998...
Ipilimumab is an approved immunotherapy that has shown overall survival benefit in patients with cutaneous metastatic melanoma two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy ipilimumab advanced seen daily clinical practice, the Dermatologic Cooperative Oncology Group conducted a II study to assess different subtypes melanoma. We undertook multicenter irrespective location primary Here we present data on pretreated...
Abstract Targeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches lacking. Furthermore, relapses drug induced side effects major challenges in the therapeutic management of patients with CTCL, creating an urgent need new effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance CTCL cells and, thus, represents a promising target CTCL. In preclinical study we showed potential dimethyl fumarate (DMF) block specifically, kill...
Detection of clonal T-cell receptor γ (TCRγ)-chain gene rearrangement is a promising approach to distinguish between cutaneous lymphomas (CTCLs) and reactive infiltrates. Despite the improved sensitivity by using polymerase chain reaction (PCR) rather than Southern blot analysis, monoclonality could be demonstrated in only 53–90 per cent CTCL biopsies recent studies. In present study, formalin-fixed, paraffin-embedded specimens 21 selected patients with clear-cut advanced-stage were analysed...
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are rare cutaneous neoplasms representing histomorphological, genetic as well epigenetic variants of a disease spectrum. Both tumors typically manifest nonspecific, often ulcerated, skin- to flesh-colored nodules in chronically sun-damaged skin elderly male patients. AFX is rather demarcated, rapidly growing tumor. PDS poorly circumscribed characterized by aggressive infiltrative growth. Fast slow growth behavior has been...
Kutane Lymphome (cutaneous lymphomas; CL) gehören zur Gruppe der extranodalen Non-Hodgkin-Lymphome, innerhalb derer sie die zweithäufigste Form darstellen (Magen-MALT-Lymphome sind häufigste extranodale Form). Die Inzidenz wird auf eine Neuerkrankung pro Jahr und 100 000 Einwohner geschätzt [1-3]. Primäre CL manifestieren sich definitionsgemäß zunächst in Haut zeigen zum Zeitpunkt Diagnosestellung nach abgeschlossener Ausbreitungsdiagnostik (Staging) keine weitere Organbeteiligung, während...
Abstract Background Primary cutaneous B‐cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%–30% all primary (PCL). Previous studies revealed impaired health‐related quality life (HRQoL) in patients diagnosed with T‐cell lymphoma (CTCL). Currently, only small‐sized investigated HRQoL CBCL and lacked detailed analysis respective subtypes. Objectives This study aims to investigate identify independent factors impairment patients. Methods One...
Summary Sebaceous gland carcinomas are rare malignant cutaneous adnexal tumors with sebocytic differentiation. The typical predilection area is the head and neck region, where sebaceous most common of skin. According to their localization a distinction made between periocular extraocular carcinomas. Muir‐Torre syndrome (MTS) should always be ruled out if it suspected. In terms prognosis, potentially aggressive clear tendency recur metastasize. Only small that have been completely resected...
A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment dapsone, hydroxychloroquine, and radiotherapy, intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that can be option for cases of faciale, especially context IgG 4-related autoimmune disease.
Zusammenfassung Mycosis fungoides (MF) und Sézary‐Syndrom (SS) sind die häufigsten Subtypen der heterogenen Gruppe kutanen T‐Zell‐Lymphome (CTCL). Mit Erweiterung Therapielandschaft in den letzten Jahren neue Behandlungsoptionen verfügbar geworden, allen voran gegen C‐C‐Chemokinrezeptor 4 (CCR4) gerichtete monoklonale Antikörper Mogamulizumab. Auf Grundlage Phase‐III‐Zulassungsstudie wird Mogamulizumab deutschen S2k‐Leitlinien für Zweitlinienbehandlung von SS MF ab Stadium IB nach mindestens...
Hyperpigmentation of the oral mucosa and gums (gingiva) is rarely biopsied by dermatologists. Yet are most common site affected hyperpigmentation1 assessed as part skin check-up.2 Many possible causes hyperpigmentation, including neoplasia, drug-induced metal deposition, or underlying diseases such lichen planus melanocanthomas,1 can only be unambiguously diagnosed through dermatopathological examination. However, there a reluctance among dermatologists regarding biopsies gingiva....
None.